Sigma® Life Science Launches Efflux Transporter Knockout Human Cell Lines in a Convenient Assay-Ready Format

Sigma® Life Science Launches Efflux Transporter Knockout Human Cell Lines in a
                        Convenient Assay-Ready Format

PR Newswire

ST. LOUIS, Nov. 20, 2012

ST. LOUIS, Nov. 20, 2012 /PRNewswire/ --Sigma-Aldrich® Corporation (Nasdaq:
SIAL) announced that Sigma Life Science, its innovative biological products
and services business, today launched its CompoZr® Transporter Knockout human
cell lines in a consumable, assay-ready plate format. The efflux transporter
knockout cell lines allow precise identification of individual
drug-transporter interactions, a critical component for understanding the
safety and efficacy characteristics of drug candidates. For more information
on the CompoZr Transporter Knockout Assay-Ready Plates,

"By offering our cell lines in a user-friendly format, these plates allow
customers to avoid handling and maintenance of cell lines, thus reducing
operative costs and time. Meeting the demands of both the occasional and the
high-throughput user, the new format helps to address many of the unmet needs
for preclinical ADME screening, safety studies, and new regulatory guidelines
in the United States and Europe," said Paul Brooks, Ph.D., Market Segment
Manager at Sigma Life Science.

The industry's current assays for drug-transporter interactions use chemical
inhibitors, which commonly interact with multiple transporters simultaneously
and thus generate ambiguous information. The efflux transporter cell lines
consist of three individual knockouts (MDR1, MRP2 and BCRP) and double
knockouts (MDR1:MRP2, MDR1:BCRP and MRP2:BCRP) that are delivered to the
customer in a convenient transwell plate format. These are ready-to-use in the
"gold standard" 21-day monolayer Caco assay for studying efflux
characteristics and so allows flexibility in the choice and trial of the
efflux transporter knockout cell lines to optimize preclinical screening.

For more information, visit

Cautionary Statement: The foregoing release contains forward-looking
statements that can be identified by terminology such as "precise
identification," "unambiguous," "easy," or similar expressions, or by
expressed or implied discussions regarding potential future revenues from
products derived there from. You should not place undue reliance on these
statements. Such forward-looking statements reflect the current views of
management regarding future events, and involve known and unknown risks,
uncertainties and other factors that may cause actual results to be materially
different from any future results, performance or achievements expressed or
implied by such statements. There can be no guarantee that CompoZr Transporter
KO cell lines or related services will assist the Company to achieve any
particular levels of revenue in the future. In particular, management's
expectations regarding products associated with CompoZr Transporter KO cell
lines or related services could be affected by, among other things, unexpected
regulatory actions or delays or government regulation generally; the Company's
ability to obtain or maintain patent or other proprietary intellectual
property protection; competition in general; government, industry and general
public pricing pressures; the impact that the foregoing factors could have on
the values attributed to the Company's assets and liabilities as recorded in
its consolidated balance sheet, and other risks and factors referred to in
Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange
Commission. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results may vary
materially from those anticipated, believed, estimated or expected.
Sigma-Aldrich is providing the information in this press release as of this
date and does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that
represents the Company's leadership in innovative biological products and
services for the global life science market and offers an array of
biologically-rich products and reagents that researchers use in scientific
investigation. Product areas include biomolecules, genomics and functional
genomics, cells and cell-based assays, transgenics, protein assays, stem cell
research, epigenetics and custom services/oligonucleotides. Sigma Life Science
also provides an extensive range critical bioessentials like biochemicals,
antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and
histology, nucleotides, amino acids and their derivatives, and cell culture

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High
Technology company whose biochemical, organic chemical products, kits and
services are used in scientific research, including genomic and proteomic
research, biotechnology, pharmaceutical development, the diagnosis of disease
and as key components in pharmaceutical, diagnostics and high technology
manufacturing. Sigma-Aldrich customers include more than 1.3 million
scientists and technologists in life science companies, university and
government institutions, hospitals and industry. The Company operates in 38
countries and has nearly 9,000 employees whose objective is to provide
excellent service worldwide. Sigma-Aldrich is committed to accelerating
customer success through innovation and leadership in Life Science and High
Technology. For more information about Sigma-Aldrich, please visit its website

Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Co, LLC registered in
the US and other countries. CompoZr is a registered trademarks of
Sigma-Aldrich Co. LLC.

SOURCE Sigma-Aldrich Corporation

Contact: For Sigma-Aldrich, Sarah Bruno, +1-314-286-7810,, For Harris D. McKinney, Inc, Alan Zachary, Ph.D.
+1-312-506-5220, or Ryan Ferrell,
Press spacebar to pause and continue. Press esc to stop.